[go: up one dir, main page]

TNSN04053A1 - Heterocyclic compounds for use in the treatment of disorders of the urinary tract - Google Patents

Heterocyclic compounds for use in the treatment of disorders of the urinary tract

Info

Publication number
TNSN04053A1
TNSN04053A1 TNP2004000053A TNSN04053A TNSN04053A1 TN SN04053 A1 TNSN04053 A1 TN SN04053A1 TN P2004000053 A TNP2004000053 A TN P2004000053A TN SN04053 A TNSN04053 A TN SN04053A TN SN04053 A1 TNSN04053 A1 TN SN04053A1
Authority
TN
Tunisia
Prior art keywords
group
alkyl
bond
heterocycle
urinary tract
Prior art date
Application number
TNP2004000053A
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Riva
Rodolfo Testa
Jeff W Corbett
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of TNSN04053A1 publication Critical patent/TNSN04053A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPOUNDS OF FORMULA (I) ARE THUS USEFUL FOR TREATING DISORDERS OF THE URINARY TRACT. IN THE COMPOUNDS I; R1 = ONE OR MORE SUBSTITUENTS SELECTED FROM H; HALOGEN; OH; ALKYL; HALOALKYL; ALKOXY; HALOALKOXY; NO2; NITRO; PHENYL; SUBSTITUTED PHENYL; HETEROCYCLE; SUBSTITUTED HETEROCYCLE; NR3R4(R3 AND R4 BEING H; ALKYL; ACYL OR ALKOXYCARBONYL); R2 = ONE OR TWO SUBSTITUENTS SELECTED FROM H; ALKYL; Y = CH2 OR A BOND; Q = CO; CS OR SO2; A = ALKYL; ALKENYL; CYCLOALKYL; CYCLOALKENYL; ARYL; HETEROCYCLIC; ALKYLAMINO; DIALKYLAMINO; ARYLAMINO OR ARYLALKYLAMINO; EACH OF WHICH IS OPTIONALLY SUBSTITUTED; N IS 1 OR 2; X = AN AMINO MOIETY SELECTED FROM FORMULA (A); (B) AND -N(R5)-CH2-(R5 = H; METHYL; BENZYL GROUP; W = BOND; N; CH; CH2; C(CN) C(OH) OR C(COCH3) (WHEN W REPRESENTS A NITROGEN ATOM OR A CH; C(CN) C(OH) OR C(COCH3) GROUP; THE GROUP Z-B ATTACHES TO THE W RING ATOM); WHEN X IS (A) OR (B); Z = BOND; O; S; CH2; CH2CH2; CO; CHOH; OCH2; NH; NHCO OR NHCONHCH2; BUT WHEN X IS -N(R5)-CH2-GROUP; Z REPRESENTS A CH2CH2 OR CH2O GROUP OR Z AND B TOGETHER REPRESENT A 2;3-DIHYDRO-BENZO[1;4]DIOXIN-2-YL GROUP; AND B IS A MONOCYCLIC OR BICYCLIC ARYL GROUP OR A MONOCYCLIC OR BICYCLIC HETEROCYCLE; EACH OF WHICH IS OPTIONALLY SUBSTITUTED
TNP2004000053A 2001-10-05 2004-04-02 Heterocyclic compounds for use in the treatment of disorders of the urinary tract TNSN04053A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI002060A ITMI20012060A1 (en) 2001-10-05 2001-10-05 NEW N-ACYLATED HETEROCYCLES
PCT/EP2002/011282 WO2003031436A1 (en) 2001-10-05 2002-10-07 Heterocyclic compounds for use in the treatment of disorders of the urinary tract

Publications (1)

Publication Number Publication Date
TNSN04053A1 true TNSN04053A1 (en) 2006-06-01

Family

ID=11448476

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000053A TNSN04053A1 (en) 2001-10-05 2004-04-02 Heterocyclic compounds for use in the treatment of disorders of the urinary tract

Country Status (32)

Country Link
US (2) US20030162777A1 (en)
EP (1) EP1432701B1 (en)
JP (1) JP2005508952A (en)
KR (1) KR20040048930A (en)
CN (1) CN1564820A (en)
AP (1) AP1705A (en)
AR (1) AR036743A1 (en)
AT (1) ATE313540T1 (en)
AU (1) AU2002346979B9 (en)
BR (1) BR0213067A (en)
CA (1) CA2458456A1 (en)
CO (1) CO5570679A2 (en)
CY (1) CY1104991T1 (en)
DE (1) DE60208221T2 (en)
DK (1) DK1432701T3 (en)
EA (1) EA200400507A1 (en)
EC (1) ECSP045095A (en)
ES (1) ES2253568T3 (en)
HR (1) HRP20040392A2 (en)
HU (1) HUP0401598A2 (en)
IT (1) ITMI20012060A1 (en)
MA (1) MA27067A1 (en)
MX (1) MXPA04002962A (en)
NO (1) NO20041833L (en)
NZ (1) NZ532511A (en)
OA (1) OA12663A (en)
PL (1) PL369763A1 (en)
SI (1) SI1432701T1 (en)
TN (1) TNSN04053A1 (en)
WO (1) WO2003031436A1 (en)
YU (1) YU27204A (en)
ZA (1) ZA200403356B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035521A1 (en) * 2000-12-22 2004-06-02 Lundbeck & Co As H DERIVATIVES OF 3-INDOLIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM
WO2003007956A1 (en) 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
ITMI20012060A1 (en) * 2001-10-05 2003-04-05 Recordati Chem Pharm NEW N-ACYLATED HETEROCYCLES
US20040058962A1 (en) * 2002-06-14 2004-03-25 Amedeo Leonardi Phenylalkylamines and pyridylalkylamines
US20040215284A1 (en) * 2003-01-30 2004-10-28 Recordati S.A. Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
UY28538A1 (en) * 2003-09-26 2005-04-29 Vertex Pharma PHENYL-PIPERAZINE DERIVATIVES AS MUSCARINIC RECEPTORS MODULATORS
RU2006124559A (en) * 2003-12-09 2008-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) NAPHTHIRIDINE DERIVATIVES AND APPLICATION OF THE INDICATED DERIVATIVES AS MUSCARINE RECEPTOR MODULATORS
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
WO2005090309A1 (en) * 2004-03-12 2005-09-29 Wyeth 1,2-dihydroquinoline derivatives and method for using the same to treat hiv infection
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
DE102005027168A1 (en) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydroquinolines
JP2009536953A (en) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 1,2,3,4-Tetrahydro-quinoline derivatives as CETP inhibitors
CA2651817A1 (en) 2006-05-11 2007-11-22 Janssen Pharmaceutica N.V. 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
PE20080212A1 (en) * 2006-06-27 2008-04-25 Sanofi Aventis UREAS DERIVATIVES OF PIPERIDINE OR PYRROLIDINE AS MODULATORS OF 11B-HYDROXIESTEROID DEHYDROGENASE TYPE 1 (11BHSD1)
FR2902790A1 (en) * 2006-06-27 2007-12-28 Sanofi Aventis Sa New N-(pyrrolidino- or piperidino-carbonyl)-tetrahydro-benzazines, are 11 beta-hydroxysteroid dehydrogenase type 1 modulators useful e.g. for treating obesity, diabetes or hypertension
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
MX2009000715A (en) 2006-07-19 2009-07-22 Osurf Ohio State University Re Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof.
RU2477282C2 (en) * 2007-08-17 2013-03-10 Эл Джи Лайф Сайенсиз Лтд. Indole compounds as cell necrosis inhibitors
US8354538B2 (en) 2008-04-24 2013-01-15 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
FR2969151B1 (en) 2010-12-17 2016-11-04 Oreal 4-AMINO DERIVATIVES AND THEIR USE FOR COLORING OXIDATION OF KERATIN FIBERS
WO2015035278A1 (en) * 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
EP3046906B1 (en) * 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Ror gamma modulators
AR107032A1 (en) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc PAD4 BICYCLIC INHIBITORS
CN108299397B (en) * 2018-03-21 2019-01-29 佳木斯大学附属第一医院 A kind of active medicine and preparation method thereof for blood pressure lowering

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1027611A (en) * 1962-01-04 1966-04-27 May & Baker Ltd Phenoxy- and phenylthio-alkylamines and acid addition salts thereof
GB1166538A (en) * 1967-06-10 1969-10-08 Pfizer Ltd Substituted Tetrahydroquinolines
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4461896A (en) * 1979-02-07 1984-07-24 Norwich Eaton Pharmaceuticals, Inc. 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
CH653021A5 (en) * 1981-04-24 1985-12-13 Delalande Sa PIPERIDINO, PIPERAZINO AND HOMOPIPERAZINO DERIVATIVES, N-SUBSTITUTED BY AN AROMATIC HETEROCYCLIC GROUP, THEIR PREPARATION METHOD AND THERAPEUTIC COMPOSITION CONTAINING THEM.
US4585773A (en) * 1984-07-11 1986-04-29 Bristol-Myers Company Isoindolinyl-alkyl-piperazines
DE3586794T2 (en) * 1984-12-21 1993-05-27 Duphar Int Res MEDICINAL PRODUCTS WITH PSYCHOTROPER EFFECT.
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5641504A (en) * 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
WO1992011843A1 (en) * 1991-01-09 1992-07-23 Alza Corporation Bioerodible devices and compositions for diffusional release of agents
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
JPH05117276A (en) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd New tricyclic quinoxalinedione derivative
US5629019A (en) * 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
JP3786684B2 (en) * 1992-05-13 2006-06-14 アルザ・コーポレーション Transdermal administration of oxybutynin
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5533971A (en) * 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
IT1270993B (en) * 1994-03-18 1997-05-26 Recordati Chem Pharm ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS
FR2729144A1 (en) * 1995-01-06 1996-07-12 Smithkline Beecham Lab New heterocyclic di:amine derivs.
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
US5780058A (en) * 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
WO1998014431A1 (en) * 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
EP0846683B1 (en) * 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxy-piperidine derivatives
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6169086B1 (en) * 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
IT1293804B1 (en) * 1997-08-01 1999-03-10 Recordati Chem Pharm DIARYLALKYL PIPERAZINS ACTIVE ON LOW URINARY TRACT
JP2001512110A (en) * 1997-08-01 2001-08-21 レコルダチ エッセ．ア．，ケミカル アンド ファーマシューティカル カンパニー 1,4-disubstituted piperazine
US6039977A (en) * 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
IL137974A0 (en) * 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6306861B1 (en) * 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
US6403594B1 (en) * 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
US6365591B1 (en) * 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
AR035521A1 (en) * 2000-12-22 2004-06-02 Lundbeck & Co As H DERIVATIVES OF 3-INDOLIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
ITMI20012060A1 (en) * 2001-10-05 2003-04-05 Recordati Chem Pharm NEW N-ACYLATED HETEROCYCLES

Also Published As

Publication number Publication date
ECSP045095A (en) 2004-08-27
ZA200403356B (en) 2004-11-08
HRP20040392A2 (en) 2004-10-31
WO2003031436A8 (en) 2004-05-27
AU2002346979B2 (en) 2005-09-29
OA12663A (en) 2006-06-19
JP2005508952A (en) 2005-04-07
CO5570679A2 (en) 2005-10-31
US20030181446A1 (en) 2003-09-25
US20030162777A1 (en) 2003-08-28
MXPA04002962A (en) 2005-06-20
SI1432701T1 (en) 2006-04-30
ATE313540T1 (en) 2006-01-15
EP1432701B1 (en) 2005-12-21
AP2004002997A0 (en) 2004-03-31
HK1067362A1 (en) 2005-04-08
AP1705A (en) 2007-01-02
AR036743A1 (en) 2004-09-29
DE60208221T2 (en) 2006-08-03
NZ532511A (en) 2005-10-28
MA27067A1 (en) 2004-12-20
PL369763A1 (en) 2005-05-02
DE60208221D1 (en) 2006-01-26
CY1104991T1 (en) 2010-03-03
HUP0401598A2 (en) 2004-12-28
EP1432701A1 (en) 2004-06-30
ITMI20012060A1 (en) 2003-04-05
BR0213067A (en) 2004-09-28
KR20040048930A (en) 2004-06-10
WO2003031436A1 (en) 2003-04-17
YU27204A (en) 2006-08-17
CA2458456A1 (en) 2003-04-17
EA200400507A1 (en) 2004-10-28
ES2253568T3 (en) 2006-06-01
DK1432701T3 (en) 2006-05-08
NO20041833L (en) 2004-07-05
AU2002346979B9 (en) 2006-03-02
CN1564820A (en) 2005-01-12

Similar Documents

Publication Publication Date Title
TNSN04053A1 (en) Heterocyclic compounds for use in the treatment of disorders of the urinary tract
ES2241796T3 (en) NEW COMPOUNDS.
ES480704A1 (en) Heteroaryloxy-acetamides, process for their preparation and their use as herbicides.
DK0842661T3 (en) Use of estrogen agonists and antagonists in the manufacture of a drug for the treatment of atherosclerosis, independent of lipid lowering
ATE282614T1 (en) PHENYL UREA AND PHENYLTHIOUREA DERIVATIVES
PE20021089A1 (en) TRIAZOLE COMPOUNDS AS CYTOKINE INHIBITORS
DE68906183D1 (en) 2'-DESOXY-5-FLUORURIDINE DERIVATIVES.
ATE102611T1 (en) THIAZOLE DERIVATIVES.
PT1468692E (en) USE OF 2,6-DIALQUIL-4-SILYPHENOLS FOR THE TREATMENT OF XANTOMA
ATE157969T1 (en) DIAMINOTRIFLUOROMETHYLPYRIMIDEINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHOSPHOLIPASE A2 INHIBITORS CONTAINING SAME
EA200100090A2 (en) New piperide-4-sulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
DE69734952D1 (en) Anilide as an ACAT inhibitor
EA200000101A1 (en) DERIVATIVES OF BENZOTHIOPHENE, THEIR APPLICATION AND COMPOSITIONS
RU2005115965A (en) Arylcarboxamide derivatives of N-benzodioxolyl, N-enzodioxanil and N-benzodioxepinyl and containing their pharmaceutical compositions
DK0395175T3 (en) thiazole
WO1988008843A3 (en) New imidazols
ATE157968T1 (en) 4-METHYL-3-PHENYL-2-OXO-3-PYRROLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND HERBICIDES CONTAINING SAME
ATE97409T1 (en) BENZODIAZEPIN ANALOGUES.
EA200200379A2 (en) Pyrimidin-4-one compounds, process for their preparation and pharmaceutical compositions containing them
EA200200462A1 (en) DERIVATIVES 2-ARILKHINOLINA, THEIR RECEIVING AND THERAPEUTIC APPLICATION
DK2298754T3 (en) Preparation of taxane derivatives
DE60116655D1 (en) CARBATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
DE69832614D1 (en) BENZOPYRANDERIVATE FOR THE TREATMENT OF PERIHPER VASCULAR DISEASE